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Protein energy wasting is frequently observed in patients with advanced chronic renal failure and end-stage renal disease. Anorexia
andreducedfoodintakearecriticalcontributingfactorsandnegativelyimpactonpatients’survival.Ghrelinisaprophagicpeptide
produced by the stomach and acting at the hypothalamic level to increase the activity of orexigenic neurons. In patients with
chronic renal disease, plasma levels are increased as a likely eﬀect of reduced renal clearance. Nevertheless, patients’ food intake
is signiﬁcantly reduced, suggesting inﬂammation-mediated resistance of hypothalamic nuclei to peripheral signals. A number of
forms of evidence show that ghrelin resistance could be overcome by the administration of exogenous ghrelin. Therefore, ghrelin
has been proposed as a potential strategy to improve food intake in chronic renal failure patients with protein energy wasting.
Preliminary data are encouraging although larger prospective clinical trials are needed to conﬁrm the results and to identify those
patients who are likely to beneﬁt most from the administration of exogenous ghrelin.
1.Introduction
The clinical course of chronic diseases is frequently compli-
cated by the progressive deterioration of nutritional status,
which signiﬁcantly impacts on patients’ morbidity, mortality
and quality of life [1]. Chronic renal failure and end-stage
renal disease are not exceptions, and up to 60% of patients
undergoing haemodialysis present with malnutrition [2]. It
is important to remember that malnutrition in end-stage
renal disease is a complex syndrome, which develops not
only from reduced energy intake like in simple starvation.
Indeed, profound metabolic changes (i.e., increased protein
catabolism, reduced muscle anabolism, increased energy
expenditure, adipose tissue loss, insulin resistance, etc.) are
critical determining factors. Consequently, normalization of
energy and protein intake, although it may improve renal
patients’ clinical outcome [3], does not result in restoration
of nutritional status and body composition.
Although the clinical phenotype of malnourished
patients with chronic renal failure can be easily recognized
andiswidelyaccepted,moreuncertaintiesexistonthetermi-
nology to be used to deﬁne this syndrome. Indeed, the word
“malnutrition” may be misleading since it may generate con-
fusion with the deterioration of nutritional status induced
by simple starvation only. The term “cachexia” has been
largely used to deﬁne disease-associated malnutrition and
has been proposed to include malnourished renal patients
as well [4]. However, considering the clinical speciﬁcities
of end-stage renal disease, a number of diﬀerent terms
have been also suggested, including “protein-energy wast-
ing” [5], “malnutrition-inﬂammation complex (or cachexia)
syndrome” [2], and “kidney disease wasting” [6]. For the
purpose of this review article and in the attempt to highlight
the analogies with other chronic conditions, the term
“cachexia” will be used to deﬁne the clinical syndrome of
weight loss, anorexia, reduced muscle performance, anemia,
and so forth, associated with chronic renal failure and end-
stage renal disease.
The pathogenesis of cachexia in renal patients is mul-
tifactorial, but anorexia and reduced food intake, as well
as profound changes in macronutrient metabolism are the
drivingforces,leadingtoapracticallynotreversiblecatabolic
status. The molecular mechanisms prompting these clinical
symptoms are increasingly being understood. As recently2 International Journal of Peptides
reviewed by Muscaritoli et al., increased levels of circulating
cytokines, metabolic acidosis, oxidative stress and insulin
resistance all appear to be variably implicated, although
the individual role of each component in the pathogenesis
of chronic kidney disease-related cachexia is still unclear
[5]. However, it appears from recent clinical data that
inﬂammation may play a pre-eminent role in triggering
the cascade of biochemical events eventually leading to the
development of anorexia and muscle wasting, that is, to
cachexia.
2. ChronicRenal FailureandCachexia
As previously mentioned, one of the most important player
in the pathogenesis of cachexia in renal patients is the
reduction of appetite, that is, anorexia. In a large study
involving a cohort of 331 patients undergoing maintenance
hemodialysis, the presence of impaired appetite (reported by
38%ofthepatientsstudied) wassigniﬁcantlyassociatedwith
reduced 12-month survival and increased hospitalization
rate[7]. Interestingly, anorexia was associated with increased
circulating levels of surrogate markers of inﬂammation, that
is, Tumor Necrosis Factor-α and C-reactive protein [7].
These data points to inﬂammation as the major trigger of the
molecular cascade of events eventually leading to anorexia
and poor outcome.
Supportive data have been published and indicate that
inﬂammation may also trigger the progressive wasting of
skeletal muscles. A number of experimental and clinical
studies consistently show that muscle mass wasting is closely
related to the presence of inﬂammation and in particular
to inﬂammation-mediated activation of speciﬁc proteases
[5, 8, 9]. In uremic rodents and patients, the ﬁrst step
in muscle protein loss is the activation of caspase-3. This
cleaves the complex structure of muscle, thereby exposing
a characteristic 14 kDa actin fragment in the insoluble
fraction of muscle. Then, the ubiquitin-proteasome system
is activated, which rapidly degrades proteins released by
caspase-3 cleavage of muscle proteins.
In adults and under physiological conditions, muscle
protein catabolism and anabolism are in equilibrium and
oﬀset each other. During disease, including end-stage renal
failure, the activation of the proteolytic pathways is not
counterbalanced by a corresponding increase of the anabolic
pathways [9]. Indeed, activation of the proteolytic systems
occurs when there is suppression of the growth-hormone-
(GH-) mediated cellular signaling pathway activated by the
insulin/insulin-likegrowthfactor(IGF)1,thephosphatidyli-
nositol 3-kinase/Akt pathway, the main muscle protein
synthesis pathway [9]. It is important to note that renal
failure is a state of GH resistance and not GH deﬁciency [10].
Some mechanisms of GH resistance are: reduced density of
GH receptors in target organs, impaired GH-activated post-
receptorJanuskinase/signaltransducerandactivatoroftran-
scription (JAK/STAT) signaling, and reduced levels of free
IGF-1dueto increasedinhibitory IGF-binding proteins [11].
End-stage renal disease is associated with a state of
insulin resistance [12]. Convincing data show that insulin
resistance is associated with increased skeletal muscle pro-
tein breakdown [13], and that inﬂammation represents a
determining factor[14].Oxidative stresscouldalsoinﬂuence
insulin sensitivity of peripheral tissues [14]. Interestingly,
inﬂammation has been demonstrated to derange mitochon-
drial function thereby favoring leakage of reactive oxygen
species [15]. Since mitochondrial dysfunction contributes to
the development of insulin resistance in skeletal muscle [16],
itappearsthatinﬂammationeitherdirectly,thatis,activating
the proteolytic systems, or indirectly, that is, favoring the
development of oxidative stress and insulin resistance, is the
main mediator of wasting in patients with chronic renal
failure. Also, considering its role in anorexia [17], it could
be speculated that disease-induced inﬂammation triggers the
cascade of biochemical events leading to cachexia, although
the speciﬁc phenotype of cachexia of each renal patients is
also determined by his/her own genetic proﬁle [17].
Supporting the role of the central nervous system as a
preferentialtargetforinﬂammationinmediatingtheonsetof
cachexia in renal patients [17], consistent evidence show that
hypothalamic melanocortin signaling triggers anorexia and
skeletal muscle wasting in experimental models of uremic
cachexia [18], and thus provide a further potential target for
the development of eﬀective therapies [19].
3. Ghrelinin the Pathogenesis of
Cachexiaof Renal Patients
Underphysiologicalconditions,energyhomeostasisistightly
controlled by the hypothalamic integration of peripheral
signals conveying to the central nervous system information
on the metabolic status of peripheral tissues [20]. In the
hypothalamus, two populations of neurons are colocalized
in the rodents’ arcuate nucleus (the infundibular nucleus in
humans): the activation of pro-opiomelancortin (POMC)
neurons promotes increased energy expenditure and satiety,
while activation of Neuropeptide Y (NPY) neurons triggers
the onset of appetite [21]. The integrated activities of
POMC and NPY neurons are controlled by a complex
mechanism: basically, POMC and NPY neurons reciprocally
respond to peptides, as well as other signals, produced in
peripheral tissues according to speciﬁc metabolic conditions,
and modulate accordingly energy homeostasis [21].
Ghrelin is a unique hormone with potent orexigenic
eﬀects [22]. It is an acylated peptide produced primarily
by gastric cells representing the endogenous ligand for the
growth hormone secretagogue receptor [23]. In addition
to stimulate the release of GH from the pituitary, ghrelin
administration stimulates food intake, and carbohydrate
utilization, and increases adiposity in rodents, suggesting
a role for this hormone in energy balance [24]. Ghrelin
inﬂuences neuronal activity through its receptor in several
areas of the brain governing energy homeostasis, including
the hypothalamus (speciﬁcally arcuate NPY neurons) [24].
Additionally, orexigenic eﬀects of ghrelin are also mediated
by modulation of hypothalamic fatty acid metabolism [25].
Under physiological conditions, acylated ghrelin, that
is, the orexigenic form of ghrelin, represents <10% ofInternational Journal of Peptides 3
circulating ghrelin, the rest being des-acylated ghrelin. Des-
acylated ghrelin has been considered as the inactive form of
ghrelin, but recent data suggest that it may exert biological
functions [26].
Considering its contributory role in determining energy
homeostasis, ghrelin has been postulated to be involved in
the pathogenesis of renal cachexia. In particular, reduced
levels of circulating ghrelin were hypothesized as a patho-
genetic mechanism mediating anorexia. Experimental and
clinical studies could not support this hypothesis, since
ghrelin levels have been consistently found increased in
patients with end-stage renal failure, undergoing or not
maintenance hemodialysis [27–29]. Supporting the lack of a
majorroleforacylatedghrelininmediatinguremicanorexia,
Bossolaetal.recentlydemonstratedthatcirculatinglevelsare
signiﬁcantly higher in uremic patients with poor/very poor
appetite when compared with uremic patients with good/fair
appetite [30]. More recently, Zabel et al. showed that in
hemodialysis patients, hunger ratings measured with visual
analogue scales correlate with markers of inﬂammation,
but no correlation can be found with circulating acylated
ghrelin [31]. On the other hand, des-acylated ghrelin has
been postulated to suppress food intake, and Muscaritoli
et al. demonstrated higher levels of des-acylated ghrelin in
anorexic uremic patients undergoing hemodialysis than in
non-anorexicpatients[32].However,theroleofdes-acylated
ghrelin in mediating uremic anorexia needs to be further
investigated.
Theacylationofghrelinismediatedbyaspeciﬁcenzyme,
ghrelin O-Acyltransferase(GOAT),whichattachesoctanoate
to serine-3 of ghrelin. Considering the potential pathogenic
role of the ratio in plasma between acylated and des-
acylated ghrelin in mediating renal cachexia [33], it would
beimportanttomeasuretheexpressionandactivityofGOAT
duringchronicrenalfailure.Unfortunately,suchdataarenot
available yet.
The mechanisms responsible for the increase of cir-
culating ghrelin levels during end-stage renal failure are
being investigated, and include impaired clearance and/or
metabolism of ghrelin in the kidney. In contrast, the
etiology of renal failure and hemodynamic parameters do
not appear have any eﬀect on plasma ghrelin levels [34].
Quite recently, the concept that ghrelin is a passive bystander
inﬂuencedbyprogressiverenalfailurehasbeenchallengedby
a series of intriguing results. Wang et al. demonstrated that
ghrelin protects against endotoxemia-induced acute kidney
injury by a likely inhibition of proinﬂammatory cytokines
[35]. Barazzoni et al. showed in nondiabetic maintenance
hemodialysis patients that insulin sensitivity is associated
negatively with systemic inﬂammation and positively with
total plasma ghrelin, suggesting a potential novel role of
ghrelin in preserving insulin sensitivity in maintenance
hemodialysis [36].
The speciﬁc role of ghrelin in muscle wasting of renal
patients with cachexia remains to be determined. Under
physiological conditions, plasma ghrelin levels relate to
muscle mass [37], likely because of its orexigenic and GH-
releasing eﬀects. More recently, Sheriﬀ et al. showed that
a ghrelin receptor agonist attenuates muscle wasting in a
model of burn injury-induced proteolysis [38]. It could
be postulated that renal cachexia is associated with ghrelin
resistance, which in turn may limit the anticatabolic eﬀects
of ghrelin, thereby exacerbating muscle proteolysis. This
hypothesis needs to be tested in experimental models and in
clinical trials.
When considered together, these data indicate that
during end-stage renal disease, increased circulating ghrelin
levels may represent an attempt to compensate and counter-
act inﬂammation, and support the use of exogenous ghrelin
as a potential therapy for renal cachexia.
4. Ghrelinin the Therapy of
Cachexiaof Renal Patients
As previously mentioned, renal failure is a state of GH
resistance, and based on the available data, it is a state of
ghrelin resistance too. However, as previously mentioned,
increased ghrelin levels could be considered as a protective
mechanism to counteract the detrimental metabolic eﬀects
induced by inﬂammation. In this regard, exogenous admin-
istration of the hormone may overcome ghrelin resistance
at target organs, improve metabolic alterations and result in
clinical beneﬁt.
Inapilotstudytestingtheeﬀectsofasinglesubcutaneous
administration of ghrelin in mild/moderate malnourished
uremic patients receiving peritoneal dialysis, energy intake
immediately doubled and was not followed by subsequent
underswing [39]. These positive preliminary results have
been conﬁrmed in a more recent 7-day trial, which con-
ﬁrmed that in malnourished dialysis patients, daily subcuta-
neous ghrelin administration immediately and signiﬁcantly
increased appetite, with an increase in energy intake noted
at the ﬁrst study meal [40]. More importantly, this eﬀect
persisted throughout the week without the occurrence of
clinically relevant side eﬀects [40]. Also, energy expenditure,
measured with free-living pulse and motion monitors, was
unchanged by ghrelin [40]. The mechanisms by which
ghrelin administration ameliorate energy intake of uremic
patients is currently being investigated. In an experimental
model of chronic renal failure, ghrelin treatment resulted
in increased food intake and an improvement in lean body
mass accrual that was related in part to a decrease in
muscle protein degradation [41]. Additionally, circulating
inﬂammatory cytokines were reduced in nephrectomized
animals by ghrelin treatment relative to saline treatment.
Finally, ghrelin-treated animals showed a decrease in the
expression of IL-1 receptor in the brainstem and a decrease
in expression of prohormone convertase 2, an enzyme
involved in the processing of proopiomelanocortin to the
anorexigenic peptide α-MSH [41]. More recently, Barazzoni
et al. found that ghrelin treatment normalized low muscle
mitochondrial enzyme activities in uremic rats [42]. This
eﬀect was associated with a lower muscle triglyceride content
and higher AKT phosphorylation. Interestingly, the eﬀects of
ghrelin on mitochondria are independent of changes in food
intake, while combined ghrelin treatment and higher food
intake were needed to enhance AKT phosphorylation [42].4 International Journal of Peptides
When these eﬀects are considered together, it appears that
ghrelin-induced muscle mitochondrial changes and lower
tissue triglycerides could favor insulin action and muscle
anabolism in the presence of improvement in food intake.
The administration of ghrelin to patients with renal
cachexia may yield clinical beneﬁts beyond its anticatabolic
eﬀects. In particular, chronic renal failure is frequently
associated with a number of cardiovascular alterations,
which may be counteracted by exogenous ghrelin. As an
example, preliminary data indicate that ghrelin restores
endothelial dysfunction in patients with obesity-related
metabolic syndrome [43].
5. Conclusion
Cachexia associated with chronic renal failure is a clinically
relevant syndrome, which negatively impacts on patients’
morbidity and mortality, and impinges on their quality of
life. The pathogenesis of this syndrome is quite complex,
but inﬂammation represents a preeminent feature triggering
the cascade of biochemical events eventually leading to
deterioration of nutritional status. Ghrelin is a unique
orexigenic hormone, whose role in cachexia is to counteract
the detrimental eﬀects on targeted organs of inﬂammation
and oxidative stress. Although a state of ghrelin resistance
appears to develop during end-stage renal failure, exogenous
administration of ghrelin appears a promising therapeutic
strategy to improve the clinical outcome of uremic patients.
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